These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3400500)

  • 41. Cervical dystonia (spasmodic torticollis). Some aspects of the natural history.
    Van Zandijcke M
    Acta Neurol Belg; 1995 Dec; 95(4):210-5. PubMed ID: 8553794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of tardive dyskinesia: use of dopamine-depleting agents.
    Fahn S
    Clin Neuropharmacol; 1983 Jun; 6(2):151-8. PubMed ID: 6133619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deep brain stimulation in the treatment of secondary dystonia.
    Zhang JG; Zhang K; Wang ZC; Ge M; Ma Y
    Chin Med J (Engl); 2006 Dec; 119(24):2069-74. PubMed ID: 17199958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tardive gait.
    Kuo SH; Jankovic J
    Clin Neurol Neurosurg; 2008 Feb; 110(2):198-201. PubMed ID: 17997030
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of the clinical course of non-Jewish, autosomal dominant torsion dystonia.
    Burke RE; Brin MF; Fahn S; Bressman SB; Moskowitz C
    Mov Disord; 1986; 1(3):163-78. PubMed ID: 3504242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
    Jankovic J; Orman J
    Neurology; 1988 Mar; 38(3):391-4. PubMed ID: 3279337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New nomenclature for drug-induced movement disorders including tardive dyskinesia.
    Chouinard G
    J Clin Psychiatry; 2004; 65 Suppl 9():9-15. PubMed ID: 15189106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs.
    Burke RE; Fahn S; Jankovic J; Marsden CD; Lang AE; Gollomp S; Ilson J
    Neurology; 1982 Dec; 32(12):1335-46. PubMed ID: 6128697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group.
    van Os J; Walsh E; van Horn E; Tattan T; Bale R; Thompson SG
    Acta Psychiatr Scand; 2000 Apr; 101(4):300-6. PubMed ID: 10782550
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baclofen in the treatment of idiopathic dystonia in children.
    Greene PE; Fahn S
    Mov Disord; 1992; 7(1):48-52. PubMed ID: 1557066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic therapy of dystonia.
    Fahn S
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):528-32. PubMed ID: 3315156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
    Müller T
    Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tardive oculogyric crises.
    FitzGerald PM; Jankovic J
    Neurology; 1989 Nov; 39(11):1434-7. PubMed ID: 2573005
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tardive stereotypy and other movement disorders in tardive dyskinesias.
    Stacy M; Cardoso F; Jankovic J
    Neurology; 1993 May; 43(5):937-41. PubMed ID: 8492949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tardive and idiopathic oromandibular dystonia: a clinical comparison.
    Tan EK; Jankovic J
    J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):186-90. PubMed ID: 10644785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tardive dyskinesia and anticholinergic drugs. A critical review of the literature.
    Yassa R
    Encephale; 1988 Sep; 14 Spec No():233-9. PubMed ID: 3063514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Drug-induced movement disorders: tardive syndromes].
    Blayac JP; Pinzani V; Peyrière H; Hillaire-Buys D
    Therapie; 2004; 59(1):113-9. PubMed ID: 15199677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hereditary progressive dystonia with marked diurnal fluctuation--consideration on its pathophysiology based on the characteristics of clinical and polysomnographical findings.
    Segawa M; Nomura Y; Tanaka S; Hakamada S; Nagata E; Soda M; Kase M
    Adv Neurol; 1988; 50():367-76. PubMed ID: 3041759
    [No Abstract]   [Full Text] [Related]  

  • 59. Tetrabenazine and movement disorders.
    Asher SW; Aminoff MJ
    Neurology; 1981 Aug; 31(8):1051-4. PubMed ID: 6455607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.
    Kazamatsuri H; Chien C; Cole JO
    Arch Gen Psychiatry; 1972 Jul; 27(1):95-9. PubMed ID: 4555831
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.